Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups.

PharmacoEconomics - 1 Dec 2020

Mital Shweta, Nguyen Hai V

Abstract excerpt

OBJECTIVE: Teplizumab was recently shown to be the first-ever drug to prevent or delay type 1 diabetes mellitus onset in at-risk individuals, especially those with certain genetic and antibody characteristics. However, its potentially high price may pose challenges for coverage and reimbursement for payers and policymakers. Thus, it is critical to investigate the cost effectiveness of this drug for different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antibodies, Monoclonal, Humanized
Share to Celiac Disease Research and Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Diabetes and associated disorders

Share to Diabetes Mellitus, Type 1

Share to HLA-DR3 Antigen

Share to Immunodeficiency and Autoimmune Disorders

Source

Identifiers

PMID: 32960433
DOI: 10.1007/s40273-020-00962-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups.PMID 32960433Read ↗

Comparison of Decision Modeling Approaches for Health Technology and Policy EvaluationSemantic proximity Read ↗

Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19Semantic proximity Read ↗

Pricing Treatments Cost-Effectively When They Have Multiple Indications: Not Just a Simple Threshold AnalysisSemantic proximity Read ↗

An Updated Economic Evaluation of HLA ‐B*58:01 Genotype Testing in Gouty Patients for Preventing Severe Allopurinol Hypersensitivity in ThailandSemantic proximity Read ↗

How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access Ahead of Patent ExpirySemantic proximity Read ↗

Are Semaglutide and Tirzepatide Cost-Effective for Weight Management? A Systematic Review and Meta-analysisSemantic proximity Read ↗

Evolving Health Policies and Pricing Dynamics in U.S. Multiple Sclerosis Therapies: A Longitudinal Analysis with Policy ImplicationsSemantic proximity Read ↗

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.Semantic proximity Read ↗

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?Semantic proximity Read ↗

Guiding the willingness to pay for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome using a cost-based-plus pricing frameworkSemantic proximity Read ↗

Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Cost-Utility and Cost-Effectiveness Analysis of disease-modifying drugs of Relapsing-Remitting Multiple Sclerosis: A Systematic ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.